A detailed history of Capital Research Global Investors transactions in Novo Nordisk A S stock. As of the latest transaction made, Capital Research Global Investors holds 54,886 shares of NVO stock, worth $4.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
54,886
Previous 50,217 9.3%
Holding current value
$4.8 Million
Previous $7.17 Million 8.82%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$119.07 - $145.42 $555,937 - $678,965
4,669 Added 9.3%
54,886 $6.54 Million
Q2 2024

Aug 13, 2024

BUY
$122.71 - $146.91 $366,166 - $438,379
2,984 Added 6.32%
50,217 $7.17 Million
Q1 2024

May 14, 2024

BUY
$102.11 - $135.92 $1.35 Million - $1.79 Million
13,181 Added 38.71%
47,233 $6.06 Million
Q4 2023

Feb 13, 2024

BUY
$87.78 - $105.45 $35,726 - $42,918
407 Added 1.21%
34,052 $3.52 Million
Q3 2023

Nov 13, 2023

BUY
$90.94 - $199.54 $1.58 Million - $3.47 Million
17,378 Added 106.83%
33,645 $3.06 Million
Q2 2023

Aug 11, 2023

BUY
$155.98 - $172.65 $39,462 - $43,680
253 Added 1.58%
16,267 $2.63 Million
Q1 2023

May 15, 2023

SELL
$132.34 - $159.14 $808,862 - $972,663
-6,112 Reduced 27.62%
16,014 $2.55 Million
Q4 2022

Feb 14, 2023

BUY
$102.55 - $135.33 $2.27 Million - $2.99 Million
22,126 New
22,126 $2.99 Million
Q3 2018

Nov 14, 2018

SELL
$46.76 - $51.24 $514 - $563
-11 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$44.29 - $50.42 $44 - $50
-1 Reduced 8.33%
11 $1,000
Q1 2018

May 15, 2018

BUY
$48.49 - $58.14 $339 - $406
7 Added 140.0%
12 $1,000
Q3 2017

Nov 14, 2017

BUY
$41.15 - $49.22 $205 - $246
5
5 $0

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $197B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Capital Research Global Investors Portfolio

Follow Capital Research Global Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital Research Global Investors with notifications on news.